36 results about "Merokeratin" patented technology

Carcinomas typically invade as a cohesive multicellular unit, a process termed collective invasion. It remains unclear how different subpopulations of cancer cells contribute to this process. We developed three-dimensional (3D) organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, K14+ cells led collective invasion in the major human breast cancer subtypes. Importantly, lumenal cancer cells were observed to convert phenotypically to invasive leaders following induction of basal epithelial genes. Although only a minority of cells within lumenal tumors expressed basal epithelial genes, knockdown of either K14 or p63 was sufficient to block collective invasion. Our data reveal that heterotypic interactions between epithelial subpopulations are critical to collective invasion. We suggest that targeting the basal invasive program could limit metastatic progression.

The invention relates to a detection kit for peripheral blood circulating tumor cells of small cell lung cancer patient and PD-L1, and belongs to the technical field of peripheral blood circulating tumor cell detection reagents. A reagent for circulating tumor cell detection comprises a CTC detection primary antibody mixture and a CTC detection secondary antibody mixture, wherein the CTC detectionprimary antibody mixture comprises Anti-Cytokinase, anti-CD45, anti-pan keratin, anti-EpCAM and a Pears immunopotentiator, and the CTC detection secondary antibody mixture comprises goat anti-mouse AlexaFluor 488, goat anti-rabbit AlexaFluor 647, a DAPI working solution and a Pears immunopotentiator. The reagent provided by the invention can greatly improve the detection efficiency, reduce the detection cost and improve the detection specificity and accuracy.

Methods and compositions for detecting tumor origin are disclosed. In certain embodiments, the origin is determined by detecting expression levels of pan-epithelial membrane mucin (MUC1), intestinal-type secretory mucin (MUC2), cytokeratin 17 (CK17), or a combination thereof. Also disclosed are methods for aiding in the determination of an appropriate course of treatment for a subject with a tumor, or for predicting a therapeutic outcome of a subject, based on the expression levels of MUC1, MUC2, CK17, or a combination thereof. Kits for use in each of these methods are also provided.

The invention provides a breast cancer cell dyeing method. The method takes anti-pan cytokeratin antibody (AE1/AE3) as the primary antibody, and adopts a horseradish peroxidase labeled rabbit antimouse antibody as the second antibody to label breast cancer cells, by means of diaminobenzidine (DAB) and hematoxylin dyeing, breast cancer cells can be dyed specifically. The invention also puts forward application of the dyeing method and a kit for carrying out the method. The method provided by the invention has the advantages of simple operation and good accuracy, can be used for detection of breast cancer micrometastatic cells in bone marrow blood and peripheral blood samples of breast cancer patients, and has important reference significance to prognosis of breast cancer.

The invention discloses a feed additive for improving the yield and quality of sheep wool, feed and a preparation method. The additive comprises processed radix aconiti lateralis, Chinese dates, loofah sponge, kudzu vine root, common bombax flowers, asarum sieboldii, gynostemma pentaphylla, holy basil, fructus aurantii and dried ginger. The feed additive takes the radix aconiti lateralis, the Chinese dates, the loofah sponge, the kudzu vine root, the common bombax flowers, the asarum sieboldii, the gynostemma pentaphylla, the holy basil, the fructus aurantii and the dried ginger as raw materials, by using the synthetic effects of the materials, rich nutrients are provided for sheep, blood circulation of the sheep and metabolism of epithelial cells are promoted, synthesis of wool keratin ispromoted, the growth speed and yield of the wool are improved, and the wool is slender and white. Meanwhile, the traditional Chinese medicine components have the effects of clearing away heat and toxic materials, tonifying middle-jiao and qi, nourishing blood and soothing the nerves and the like, can improve the immunity of sheep bodies, absorption and utilization of the effective components suchas nutritional ingredients and microelements in the feed for the sheep are improved, the growth speed and yield of the wool are further increased, and the economic benefit of sheep breeding is greatly improved.

The invention discloses a method for improving the enzymatic modification efficiency of wool keratin, which belongs to the technical field of biochemical modification of textile materials. By utilizing the characteristics of disulfide bonds rich in a structure of the wool keratin, an amino group is introduced into the structure of the keratin by performing a click chemical reaction on a sulfhydrylgroup formed by reduction and propargylamine, so that the number of acting sites of a TGase enzymatic reaction is increased, and the enzymatic modification efficiency of the wool keratin is improved.The method is high in operating reaction efficiency, has no toxicity and is easily controlled, and the problems of residual of by-products, environmental pollution, fabric strength damage and the like caused by a side reaction of the chemical reaction, are avoided, therefore, the method has strong practical value.

The invention discloses a cervical cancer screening method, which comprises the following steps of: taking menstrual blood, and detecting CA15-3(Carbohydrate antigen 15-3, carbohydrate antigen 15-3), CEA (Carcino-embryonic antigen), CA125 (Carbohydrate antigen 125), CYFRA21-1 (cytokeratin 19 fragment, cytokeratin fragment), squamous cell carcinoma associated antigen (SCCA), Her-2 (human epidermal growth factor receptor-2 of protooncogene), TP53 (Tumor protein 53) gene, APC (Adenomatous polyposis coli) gene, HPV DNA gene, and TCT(liquid based cytology) detection in the menstrual blood, and the illness risk of cervical cancer can be prompted. The method has no radiation damage to human bodies, and is short in detection time and low in cost. As the menstrual blood is very convenient and noninvasive to obtain, women can detect once a month, so that the women can know the risk of cervical cancer as soon as possible and take prevention and treatment measures.

The invention belongs to the technical field of biomedical detection, and particularly relates to a marker and a detection kit for detecting bladder cancer. The marker provided by the invention comprises a nuclear matrix protein 22 (NMP22), a carcino-embryonic antigen (CEA), a bladder tumor antigen (BTA) and a cytokeratin 19 fragment (CYFRA21-1). According to the detection kit, acridinium ester is adopted for direct chemiluminescence, an antibody (antigen) is directly labeled by the acridinium ester, after immune reaction with a corresponding antigen (antibody) of a sample to be detected, a coated antibody-antigen to be detected-acridinium ester labeled antibody compound is formed, excitation liquid is added, and decomposition and luminescence can be realized without a catalyst. A combination of multiple tumor markers is established, the detection specificity and sensitivity of bladder cancer are improved through combined detection of multiple indexes, when urine of a bladder cancer patient is detected, the sensitivity and specificity are high, and early screening, treatment effect and postoperative recurrence of the bladder cancer patient can be dynamically monitored.

Provided are a pretreatment method for detecting the number of cells containing Ki-67 protein-positive nuclei using Ki-67 antibody; a method for the detection; a kit to be used in the detection method; and determination of a therapy regimen using the aforesaid method. Attempts were made to activate Ki-67 antigen with the use of an enzyme having been considered as inappropriate for the activation thereof. By pretreating a sample with an enzyme not recognizing the epitope of MIB-1 (a rare cutter enzyme), the antigen activation of Ki-67 antigen was enhanced, while enhancing the antigenicity of other antigens including a cytokeratin too. As a result, a method for more objectively and more universally quantifying Ki-67-positive cells at higher reproducibility, said method comprising isolating cell nuclei from an FFPE section while enhancing the antigenicity and performing a reaction between Ki-67 protein, i.e., the target, existing in the cell nuclei with a fluorescently labeled antibody, has been completed.

The invention belongs to the technical field of biological detection, and discloses a fluorescent quantum dot nanoprobe, a preparation method thereof and application of the fluorescent quantum dot nanoprobe in detection of circulating tumor cells. The detection probe comprises a water-soluble quantum dot modified by an antibody; the antibody can specifically bind to a circulating tumor cell surface marker, such as an anti-EpCAM antibody, an anti-EGFR antibody, an anti-cytokeratin CK-8, CK-18 and CK-19 antibody, an anti-tumor cell glycoprotein (TAG) antibody or an anti-lactoglobulin antibody; more preferably, an anti-EpCAM antibody; the water-soluble quantum dots are selected from near-infrared two-region fluorescent water-soluble non-toxic quantum dots. An antibody-modified water-soluble near-infrared two-region fluorescent non-toxic quantum dot material is used as a fluorescent probe, and the number of circulating tumor cells is detected by virtue of the change of the fluorescence intensity of the probe through an antigen-antibody specific recognition effect.

The invention relates to a method for obtaining artificial skin through stem cell in-vitro differentiation and application of the method, and provides a method for differentiating stem cells to skin cells in vitro to obtain artificial skin and application. The culture method comprises the following steps: S1, subculturing mesenchymal stem cells until 60-90% of cells are merged, and collecting P3 generation cells to prepare a mesenchymal stem cell suspension; S2, attaching, specifically, placing acellular dermis and the mesenchymal stem cell suspension in an ultralow adsorption reactor, and carrying out culturing by using a complete culture medium; and S3, inducing the mesenchymal stem cells loaded by the acellular dermis to differentiate to skin cells in vitro, specifically, changing liquid by using an induction culture solution, wherein the induction culture solution takes a KFSM culture medium as a basic culture medium, astragalus injection with the concentration of 30-50 g/L and fetal calf serum with the volume fraction of 1-3% are added, and the induction culture time is 14 days. TM4SF1 and broad-spectrum cytokeratin expression are positive, the obtained artificial skin is moresimilar to cells forming skin tissues, and a better treatment effect can be achieved.

The invention provides a marker and kit for early hepatic fibrosis diagnosis and application.The marker comprises at least one of cytokeratin 19 and a fragment antigen CYFRA21-1 of the cytokeratin 19,and at least one of the liver fibrosis early diagnosis markers is differentially expressed in a test sample and a control sample. The marker for early diagnosis of hepatic fibrosis can realize diagnosis of early hepatic fibrosis.

The invention relates to a cocktail immunohistochemical kit for diagnosing breast cancer, which comprises a peroxidase sealing agent, a combined primary antibody, a combined secondary antibody, a DAB chromogenic substrate, a DAB chromogenic buffer solution, a fast red chromogenic agent, a fast red chromogenic activator, a fast red buffer solution and a hematoxylin restaining solution, wherein the combined primary antibody comprises a mouse anti-human cytokeratin 7 monoclonal antibody, a mouse anti-human P63 monoclonal antibody and a rabbit anti-human MHC monoclonal antibody; the combined secondary antibody comprises an anti-mouse secondary antibody polymer marked by HRP and an anti-rabbit secondary antibody polymer marked by AP. According to the kit, the cocktail combined primary antibody is adopted, the expression conditions of three antigen targets CK7, P63 and MHC can be detected on the same tissue slice at the same time, the use amount of samples is reduced, the difference caused by different slices is avoided, the problem of poor dyeing repeatability of tiny tissue samples is solved, normal tissue and cancer tissue can be visually and clearly distinguished, a more comprehensive and reliable diagnosis basis is provided for pathologists, and the diagnosis accuracy is improved.

An immortalized sweat gland myoepithelial cell which expresses α-SMA and pan-cytokeratin and has a sphere forming ability after subculture at least 5 times. A method for producing immortalized sweat gland myoepithelial said method comprising: while culturing a cell structure, wherein sweat gland myoepithelial cells are exposed on a surface, in a state of being suspended in a medium, transferring an immortalizing gene into the cells; and then culturing the transgenic structure thus obtained in a state of being suspended in the medium to thereby obtain immortalized sweat gland myoepithelial cells.